Age-specific mixing generates transient outbreak risk following critical-level vaccination.
Measles elimination goals have been adopted in a range of countries, sub-regions, and regions since the WHO declared an elimination goal by 2015 or 2020. All countries attempt to achieve and maintain high coverage through routine immunization programmes. This routine strategy, however, does not ensure the elimination goal of measles. Many developed countries, such as the United States, that have succeeded in interrupting measles transmission earlier, are now experiencing outbreaks with an increasing number of cases. Using a stochastic, age-structured model of measles vaccination dynamics, we explore and characterize the transient dynamics of measles susceptibility in the years following the implementation of routine vaccination at the herd immunity threshold. We demonstrate how a population could face risks of potentially large outbreaks even within few years of vaccination. We characterize different risk profiles depending on the incidence pattern in the years prior to vaccination. These results suggest that the classic critical vaccination threshold is necessary to achieve herd immunity, but not sufficient to prevent long periods of transient, super-critical dynamics. Our results suggest the need of future work for more careful monitoring of the impacts of current immunization programmes, and developing models that take into account more complicated vaccination strategies, demographic factors, and population movements.
Department of Mathematics,School of Natural Sciences,Shiv Nadar University,India.
S
S
Bhattacharyya
Center for Infectious Disease Dynamics,Pennsylvania State University,PA,USA.
M J
MJ
Ferrari
D000367:Age Factors; D004196:Disease Outbreaks; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D005260:Female; D014943:Global Health; D006801:Humans; D032521:Immunity, Herd; D008297:Male; D008457:Measles / Q000453:epidemiology* / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D008962:Models, Theoretical; D018570:Risk Assessment
D008458:Measles Vaccine
Effective reproductive rate; honeymoon period; measles vaccination; transient risk
Theor Ecol. 2015 May;8(2):261-271
26140058
Science. 2000 Jan 28;287(5453):667-70
10650003
Emerg Infect Dis. 2013 Mar;19(3):357-64
23618523
Vaccine. 2013 Apr 12;31(16):2097-102
23273970
J R Soc Interface. 2005 Sep 22;2(4):281-93
16849186
J Infect Dis. 2004 May 1;189 Suppl 1:S27-35
15106086
Vaccine. 2003 Nov 7;21(31):4597-603
14575773
Am J Public Health. 2000 Oct;90(10):1521-5
11029981
MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57
9639369
Epidemiol Infect. 1988 Feb;100(1):111-33
3338500
Lancet. 1995 Feb 4;345(8945):272
7837860
Lancet. 2012 Jun 9;379(9832):2173-8
22534001
PLoS Comput Biol. 2012;8(9):e1002673
23028275
Int J Epidemiol. 2002 Oct;31(5):968-76
12435769
Epidemiol Infect. 1988 Jun;100(3):419-42
3378585
J Infect Dis. 2004 May 1;189 Suppl 1:S251-7
15106119
N Engl J Med. 2006 Aug 3;355(5):447-55
16885548
Br Med Bull. 1998;54(3):545-56
10326283
Rev Inst Med Trop Sao Paulo. 2012 Oct;54 Suppl 18:S22-7
23011456
Vaccine. 2014 Apr 1;32(16):1798-807
24530936
Vaccine. 2011 Dec 30;29 Suppl 4:D91-6
22185837
J Infect Dis. 2011 Jul;204 Suppl 1:S476-82
21666203
Int J Infect Dis. 2006 Mar;10(2):148-55
16275043
J Infect Dis. 2011 Jul;204 Suppl 1:S107-15
21666151
MMWR Morb Mortal Wkly Rep. 1999 Dec 31;47(53):ii-92
10682828
PLoS Med. 2007 Jan;4(1):e16
17199407
Emerg Infect Dis. 2013 Feb;19(2):202-9
23343504
Br Med Bull. 2002;62:187-99
12176860
BMJ. 2015 Jan 23;350:h436
25616478
Rev Panam Salud Publica. 2000 Jun;7(6):359-65
10949895
Int J Epidemiol. 1994 Feb;23(1):185-93
8194915
J Math Biol. 1989;27(3):233-58
2746140
MMWR Morb Mortal Wkly Rep. 1999 Sep 3;48(34):749-53
10499786
Am J Epidemiol. 2014 Jun 1;179(11):1375-82
24786800
BMJ. 2015 Feb 03;350:h622
25646696
Am J Epidemiol. 1999 Dec 1;150(11):1250-7
10588086
PLoS Med. 2008 Mar 25;5(3):e74
18366252